Open an account

Rafael Holdings

RFL · NYSE

$1.29+$0.00 (+0.00%)TodayMarket closed ·
Prev close $1.29

About RFL

Rafael Holdings, Inc. owns an interest in clinical and early-stage pharmaceutical companies. The company is headquartered in Newark, New Jersey and currently employs 21 full-time employees. The company went IPO on 2018-03-12. The firm's segments include Healthcare, Infusion Technology and Real Estate. The Company’s lead candidate is Trappsol Cyclo, which is being evaluated in clinical trials for the potential treatment of Niemann-Pick Disease Type C1 (NPC1), a rare, fatal and progressive genetic disorder. The Healthcare segment comprises equity interests in LipoMedix Pharmaceuticals Ltd., Barer Institute Inc., Cornerstone Pharmaceuticals, Inc., Cyclo, and Rafael Medical Devices, LLC. The Real Estate segment consists of the Company’s real estate holdings, which comprise a portion of one commercial building in Israel. The Infusion Technology segment comprises equity interests in Day Three Labs, Inc. LipoMedix Pharmaceuticals Ltd. is a clinical-stage pharmaceutical company.

Employees
21
Headquarters
Newark, New Jersey
Listed
Mar 12, 2018
Sector
Health Care
Industry
Pharmaceuticals
Website
rafaelholdings.com

RFL key statistics

Market cap
67.09M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
237.35K
Volume
32.47K
Open price
$1.29
High today
$1.35
Low today
$1.29
52 Week high
$3.96
52 Week low
$1.12

Rafael Holdings (RFL) at a glance

As of Oct 20, 2026, Rafael Holdings (RFL) shares are priced at $1.29, giving the company a market cap of 67.09M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $1.29 and $1.35. The current price is 0.1% above the day's low and 4.4% below its high.

Volume so far is 32.47K shares, below the average of 237.35K shares a day.

Over the past year Rafael Holdings has ranged from $1.12 to $3.96, and now sits 6% of the way up that range.

Rafael Holdings met or beat analyst EPS estimates in 0 of the last 2 quarters. In Q1 FY25 it reported -$0.37 per share against an estimate of $0.00.

RFL earnings

Earnings per share, reported against the analyst estimate

Didn’t beat the estimate in any of the last 2 quarters.

  1. Q1 FY23: reported -$0.22 per share against an estimate of $0.00
  2. Q1 FY25: reported -$0.37 per share against an estimate of $0.00

RFL news

  • Press releaseGlobe Newswire

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rafael Holdings, Inc. - RFL

  • Press releasePRNewswire

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rafael Holdings, Inc. - RFL

  • Press releaseGlobe Newswire

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rafael Holdings, Inc. - RFL

  • Avi Kapoor

    Crude Oil Rises Over 1%; Conagra Brands Earnings Top Views

  • Vandana Singh

    Why Is Rafael Stock Falling Wednesday?

  • Press releaseGlobe Newswire

    Rafael Holdings Announces Patent Licensing Agreement with MIT for "Small Molecules to Improve Myelination in ApoE4 positive Alzheimer's Disease"

  • 12 Health Care Stocks Moving In Tuesday's Pre-Market Session

  • 12 Health Care Stocks Moving In Monday's Intraday Session

Similar companies

Companies in the same industry as Rafael Holdings

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.